Company intelligence / Profile preview
U-Factor
- Ownership
- Private
- Development stage
- Other
Overview
U-Factor has developed a proprietary stem cell-conditioned medium called "U-Factor® solution," with demonstrated safety and potential efficacy in ALS patients. In a retrospective cohort study involving 24 ALS patients, the decline in function was slower than expected, with some experiencing symptom improvement. Only mild adverse events were reported. The company is advancing global clinical trials and regulatory filings for this regenerative therapy.
- Therapeutic areas
- OphthalmologyGastroenterologyNeurology
- Modalities
- Stem cell culture supernatant (conditioned medium)Biologic
- Industry
- Biotech
Drug pipeline
3 assets2 more assets in the full pipeline.
Request access →Partnerships
Beyond the preview
Go deeper on U-Factor.
Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.
Clinical trials
Full profile accessFollow clinical development from trial design and recruitment through results.
- Trial phase
- Status
- Readouts
Licensing & deals
Full profile accessExplore licensing agreements, acquisitions, and the assets behind each deal.
- Partners
- Deal terms
- Milestones
Funding history
Full profile accessTrace financing activity and the investors behind a company’s development.
- Funding rounds
- Investors
- Capital raised
Competitive landscape
Full profile accessCompare peer pipelines by target, modality, and therapeutic area.
- Peer companies
- Targets
- Pipeline overlap
Technologies & patents
Full profile accessExplore technology platforms and the patent landscape around relevant assets.
- Platforms
- Patents
- Assignees
Research & analysis
Full profile accessConnect company news and source material to the questions you’re investigating.
- Company news
- Sources
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on U-Factor.